This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

NeoStem And Progenitor Cell Therapy (PCT) To Present At Multiple April Conferences

Stocks in this article: NBS

NEW YORK, April 1, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that the Company and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), will present at multiple upcoming conferences in April.

Kingston Advisors Dearborn Annual New York Healthcare Investment Forum

  • Date and Time: Monday, April 7, 2014, 9:30 AM EDT
  • Venue: W Times Square, 1567 Broadway, New York, NY
  • Topic: Company Presentation

Workshop: Automation of GMP Cell Production

  • Date and Time: Tuesday, April 15, 2014, 9:15 AM EDT
  • Venue: McMaster University, Hamilton, Ontario
  • Speaker: Robert Shaw, Vice President, Commercial Development, PCT
  • Topic: Beyond the Boutique: Towards a Vision for Advancing the Global Cell Therapy Industry 

The 18th International Vascular Biology Meeting (IVBM)

  • Date and Time: Thursday, April 17, 2014, 2:15 – 4:15 PM JST
  • Venue: Miyakomesse, Kyoto, Japan
  • Speaker: Dr. Douglas Losordo, Chief Medical Officer, NeoStem
  • Topic: Therapeutic Angiogenesis and Regeneration
  • Website:

GTC Stem Cell Summit

  • Date and Time: Thursday, April 24, 2014, 10:45 AM EDT
  • Venue: Hyatt Regency Cambridge, 575 Memorial Drive, Cambridge, MA
  • Speaker: Dr. Douglas Losordo, Chief Medical Officer, NeoStem
  • Topic: Advances in Adult & Pluripotent Stem Cells
  • Website:

GTC Diabetes Summit

  • Date and Time: Thursday, April 24, 2014, 4:15 PM EDT
  • Venue: Hyatt Regency Cambridge, 575 Memorial Drive, Cambridge, MA
  • Speaker: Dr. Douglas Losordo, Chief Medical Officer, NeoStem
  • Topic: Partnering Opportunities in Diabetes Drug Development  - Autologous Cell Therapy: Leveraging Innate Tissue Repair Capacity to Modify Disease Natural History
  • Website:

ISCT 2014 – 20th Annual Meeting

  • Date and Time: Friday, April 25, 2014 10:45 AM CET
  • Venue: Le Palais des Congrès de Paris, Paris, France
  • Speaker: Dr. Robert Preti, Chief Scientific Officer, NeoStem and PCT; President, PCT
  • Topic: Strategies for Commercialization: Managing COGs and the Impact of Product Decisions from Phase I to Commercial Supply
  • Website:

Poster presentation at ISCT 2014

  • Poster Title: "Characterization of bone marrow-derived CD34+ cells with different migratory potential by microRNA fingerprinting and antibody array."
  • Date and Time: Thursday, April 24, 2014 5:00 - 6:30 PM CET (Poster Hall)
  • Presenter:  Dr. Courtney LeBlon, Process Development Scientist, PCT

2014 Allicense Conference

  • Date: Wednesday, April 30, 2014
  • Venue: Palace Hotel, San Francisco, CA
  • Speaker: Dr. Robin Smith, Chairman and CEO, NeoStem
  • Session #1: Keynote Address: Leveraging the Public Markets to Finance Development (9:10 AM PDT)
  • Session #2: Panel on Public Markets (11:30 AM PDT)
  • Website:

About NeoStem, Inc.

NeoStem is a leader in the emerging cellular therapy industry, pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation.   

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's ability to develop and grow its business, the successful development of cellular therapies, including with respect to the Company's research and development and clinical evaluation efforts in connection with the Company's CD34 Cell Program, T Regulatory Cell Program, VSEL™ Technology for tissue regeneration and other cell therapies, including the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the performance and planned expansion of the Company's contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 13, 2014 and in the Company's periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

CONTACT: Investor Contact:
         LifeSci Advisors, LLC
         Michael Rice
         Founding Partner
         Phone: +1-646-597-6979
         Media Contact:
         NeoStem, Inc.
         Eric Powers
         Manager of Communications and Marketing
         Phone: +1-212-584-4173

NeoStem Inc. Logo

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,959.44 +154.64 0.87%
S&P 500 2,076.42 +5.77 0.28%
NASDAQ 4,776.4780 +11.0980 0.23%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs